Soluble protein manufacturer AbSci lands $5.1M in Series A financing


AbSci, which manufactures soluble microbial proteins, said it secured $5.1 million in a round of Series A financing that it plans to use to speed up commercialization of its protein expression platform used in biopharmaceutical manufacturing.

The fundraising was led by Phoenix Venture Partners, which is based in Silicon Valley, the company said in a press release.

Portland, OR-based AbSci is the developer of a protein manufacturing platform that substantially reduces the production costs of therapeutic proteins and antibodies used in a wide range of medical treatments, including those for cancer, hormone therapies, diabetes and autoimmune disorders.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

“AbSci’s technology enables greater manufacturing flexibility and dramatically more efficient use of existing manufacturing infrastructure,” Dr. Zach Jonasson, general partner at Phoenix Venture, said in a statement. As part of the financing deal, Jonasson has been named to AbSci’s board of directors.

Dubbed SoluPro, the E.coli expression platform is capable of producing soluble, active therapeutic proteins at high yields. The company said the new funding will be used for additional development of the system and commercial production of insulin and other therapeutic proteins.

- check out the release

Related Article:
China-based VC firm WuXi Healthcare makes coast-to-coast U.S. investments

Suggested Articles

For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.